Real-world usage profile of flecainide in a cardiology outpatient setting: a retrospective observational study

Real-world data on flecainide use in older, multimorbid patients remain limited. This retrospective observational study analyzed the electronic medical records of 31 adults prescribed flecainide at a cardiology outpatient clinic (February–May 2025). The cohort was predominantly older (mean age 71.9 ± 9.5 years) and female (71.0%), and most patients had arterial hypertension (83.9%). Therapy modification was required in 32.3% of patients; higher diastolic blood pressure was associated with modification (OR 1.15 per 1 mmHg, 95% CI: 1.01–1.30), but this association was not observed in a complete-case sensitivity analysis. Adverse drug reactions were documented in 12.9% of patients, none of which were attributable to flecainide. Clinical improvement was documented in 14 of 21 patients with follow-up data (66.7%), and therapy modification was associated with lower odds of improvement (adjusted OR 0.046, 95% CI: 0.003–0.618). These exploratory findings suggest acceptable short-term tolerability of flecainide in carefully selected older patients.

Authors

Institutions

Publication Details

Journal
Pharmacia
Published
2026-11-16
DOI
https://doi.org/10.3897/pharmacia.73.e216973
Primary Topic
Pharmaceutical Practices and Patient Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real-world usage profile of flecainide in a cardiology outpatient setting: a retrospective observational study

Violeta Getova-Kolarova, Evgeni Grigorov, Илко Гетов, Emilia Naseva
Pharmacia
Pharmaceutical Practices and Patient Outcomes
article

Real-world usage profile of flecainide in a cardiology outpatient setting: a retrospective observational study

Violeta Getova-Kolarova, Evgeni Grigorov, Илко Гетов, Emilia Naseva
article en

Abstract

Real-world data on flecainide use in older, multimorbid patients remain limited. This retrospective observational study analyzed the electronic medical records of 31 adults prescribed flecainide at a cardiology outpatient clinic (February–May 2025). The cohort was predominantly older (mean age 71.9 ± 9.5 years) and female (71.0%), and most patients had arterial hypertension (83.9%). Therapy modification was required in 32.3% of patients; higher diastolic blood pressure was associated with modification (OR 1.15 per 1 mmHg, 95% CI: 1.01–1.30), but this association was not observed in a complete-case sensitivity analysis. Adverse drug reactions were documented in 12.9% of patients, none of which were attributable to flecainide. Clinical improvement was documented in 14 of 21 patients with follow-up data (66.7%), and therapy modification was associated with lower odds of improvement (adjusted OR 0.046, 95% CI: 0.003–0.618). These exploratory findings suggest acceptable short-term tolerability of flecainide in carefully selected older patients.

PharmaciaVol. 73
Medical University of Varna (BG), Medical University of Sofia (BG)
European Commission, NextGenerationEU
Good health and well-being
Pharmaceutical Practices and Patient Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon